Identification of Biomarkers for HER2-Negative Advanced Breast Cancer Is Influenced by Race: A Real-World Study

Conference Correspondent  - ASCO 2021 - Breast Cancer

Lack of access to appropriate medical care among African-American patients with advanced breast cancer greatly contributes to high mortality rates within this demographic. Identification of actionable biomarkers has led to a paradigm shift in cancer treatments. For HER2-negative disease, biomarker testing has become available, but the impact of race on biomarker testing rates in HER2-negative advanced breast cancer patients has not been fully assessed. Biomarker testing provides the opportunity to deliver an individualized approach to treatment.

Records of 378 patients were evaluated and divided into 3 cohorts by race (white [n = 231], African American [n = 88], and other [excluded from analysis due to small sample size]). The average age of the patients was 64 years and most (54%) were receiving first-line therapy while 45% were receiving second- or later-line treatment. Actionable mutations such as BRCA1/2, PIK3CA, and PD-L1 were compared with white and African-American patients. The most common hormone receptor profile was HR-positive/HER2-negative advanced breast cancer (77%). Another 20% had advanced triple-negative breast cancer (TNBC), and 3% had advanced disease with an unknown receptor status. African-American patients had significantly greater rates of advanced TNBC than white patients (27% vs 18%, respectively; P <.05). It was also found that among African-American patients aged ≥65 years, there were lower testing rates for BRCA1/2 mutations compared with white participants (race: 66% vs 79%, respectively; P <.01). However, the BRCA1/2 mutation positivity rate was higher in African-American patients compared with white patients (30% vs 22%, respectively; P = .15) Similarly, testing in African Americans for PIK3CA mutations (44% vs 50%; P = .31) and PD-L1 (54% vs 59%; P =. 43) were also lower compared with white patients, and the positivity rate for PIK3CA mutation was also lower for African-American patients (8% vs 11%; P = .78).

Biomarker testing in the African-American HER2-negative breast cancer population will provide an important screening tool to reduced mortality rates. In the study reported here, investigators observed that African-American patients had lower testing rates compared with white patients for all biomarkers assessed (BRCA1/2, PIK3CA, PD-L1). It should be noted that African-American patients presented with a higher than expected BRCA1/2 mutation positivity rate than previously reported in the literature. Researchers conclude that including somatic BRCA1/2 mutation and a high-risk patient population may have contributed to this divergence from reported data. The data indicate a gap in biomarker testing in HER2-negative tumors due to race. Validation of biomarkers based on racial identification has the potential to introduce individualization in management of HER2-negative advanced breast cancer in African-American populations.

Source: Mahtani RL, Niyazov A, Lewis K, et al. Impact of race on biomarker testing among HER2– advanced breast cancer (ABC) patients (pts) in the United States: results from a real-world study. American Society of Clinical Oncology Virtual Meeting; June 4-8, 2021. Abstract 10598.

Related Items
Inflammatory Responses to Neoadjuvant Chemotherapy Can Be Regulated by Moderate Physical Exercise Prior to Surgery
Conference Correspondent  published on June 7, 2021 in ASCO 2021 - Breast Cancer
Assessment of Factors That Influence Psychosocial Function in Breast Cancer Patients After Treatment
Conference Correspondent  published on June 7, 2021 in ASCO 2021 - Breast Cancer
Treatment with Alpelisib plus Fulvestrant Achieves Long-Term Disease Control in Endocrine-Resistant (HR-Positive/HER2-Negative) Advanced Breast Cancer
Conference Correspondent  published on June 7, 2021 in ASCO 2021 - Breast Cancer
Behavioral Interventions Demonstrate Improved Long-Term Adherence to Adjuvant Endocrine Therapy Among Women with HR-Positive Breast Cancer
Conference Correspondent  published on June 7, 2021 in ASCO 2021 - Breast Cancer
Assessment of Oncology Patient Satisfaction with Telehealth Visits
Conference Correspondent  published on June 7, 2021 in ASCO 2021 - Breast Cancer
Need for Improved Access to Cancer Screening Tools for Minorities with Socioeconomic Barriers to Medical Care
Conference Correspondent  published on June 7, 2021 in ASCO 2021 - Breast Cancer
Novel and Clinically Relevant Measure of Perceived Fatigability Reveals Benefit of Exercise in Breast Cancer Survivors
Conference Correspondent  published on June 7, 2021 in ASCO 2021 - Breast Cancer
Association of Stage of Breast Cancer Diagnosis and Socioeconomic Status in French Women
Conference Correspondent  published on June 7, 2021 in ASCO 2021 - Breast Cancer
Alpelisib Overcomes Resistance to CDK4/6 Inhibitors in HR-Positive/HER2-Negative Advanced Breast Cancer Patients
Conference Correspondent  published on June 7, 2021 in ASCO 2021 - Breast Cancer
Demographic and Clinical Factors Among Women with Breast Cancer Create a Gap Between Referrals and Completion of Genetic Counseling and Testing
Conference Correspondent  published on June 4, 2021 in ASCO 2021 - Breast Cancer
Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.